

Roberto Gambino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8091996/publications.pdf>

Version: 2024-02-01

181
papers

14,681
citations

30070

54
h-index

19190

118
g-index

184
all docs

184
docs citations

184
times ranked

18944
citing authors

#	ARTICLE	IF	CITATIONS
1	Protective effect of the tunneling nanotube-TNFAIP2/M-sec system on podocyte autophagy in diabetic nephropathy. <i>Autophagy</i> , 2023, 19, 505-524.	9.1	28
2	Protective Role of the M-Secâ€Tunneling Nanotube System in Podocytes. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1114-1130.	6.1	12
3	Compositional Characteristics and Antioxidant Activity of Edible Rose Flowers and Their Effect on Phenolic Urinary Excretion. <i>Polish Journal of Food and Nutrition Sciences</i> , 2021, , 383-392.	1.7	3
4	Acute assessment of subjective appetite and implicated hormones after a hypnosis-induced hallucinated meal: a randomized cross-over pilot trial. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020, 21, 411-420.	5.7	2
5	Diabetic ketoacidosis with SGLT2 inhibitors. <i>BMJ, The</i> , 2020, 371, m4147.	6.0	42
6	Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression. <i>PLoS Medicine</i> , 2020, 17, e1003461.	8.4	28
7	Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2019, 365, l1328.	2.3	74
8	Rs12778366 single nucleotide polymorphism of Sirtuin 1 (SIRT1) and response to resveratrol supplementation in patients with type 2 diabetes mellitus. <i>Acta Diabetologica</i> , 2019, 56, 963-966.	2.5	7
9	The microbiota composition of the offspring of patients with gestational diabetes mellitus (GDM). <i>PLoS ONE</i> , 2019, 14, e0226545.	2.5	45
10	Angiotensin II Type 1 Receptor rs5186 Gene Variant Predicts Incident NAFLD and Associated Hypertension: Role of Dietary Fat-Induced Pro-Inflammatory Cell Activation. <i>American Journal of Gastroenterology</i> , 2019, 114, 607-619.	0.4	22
11	MICROBIOTA INTESTINALE E RISCHIO CARDIOVASCOLARE. <i>Il Diabete</i> , 2019, 3, .	0.0	0
12	Specialized Proresolving Mediators: Enhancing Nonalcoholic Steatohepatitis and Fibrosis Resolution. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 387-401.	8.7	36
13	Impact of sirtuin-1 expression on H3K56 acetylation and oxidative stress: a double-blind randomized controlled trial with resveratrol supplementation. <i>Acta Diabetologica</i> , 2018, 55, 331-340.	2.5	56
14	Targeting mitochondrial pyruvate carrier in nonalcoholic steatohepatitis: Growing evidence and future challenges. <i>Hepatology</i> , 2018, 67, 2055-2055.	7.3	0
15	Impaired taste sensation in type 2 diabetic patients without chronic complications: a caseâ€control study. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 765-772.	3.3	27
16	Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance. <i>Hepatology</i> , 2018, 67, 145-158.	7.3	296
17	Effects of resveratrol on bone health in type 2 diabetic patients. A double-blind randomized-controlled trial. <i>Nutrition and Diabetes</i> , 2018, 8, 51.	3.2	48
18	Reversal of albuminuria by combined AM6545 and perindopril therapy in experimental diabetic nephropathy. <i>British Journal of Pharmacology</i> , 2018, 175, 4371-4385.	5.4	22

#	ARTICLE	IF	CITATIONS
19	Incidence of diabetes mellitus, cardiovascular outcomes and mortality after a 12-month lifestyle intervention: A 9-year follow-up. <i>Diabetes and Metabolism</i> , 2018, 44, 449-451.	2.9	4
20	Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2018, 155, 282-302.e8.	1.3	216
21	Changes in the gut microbiota composition during pregnancy in patients with gestational diabetes mellitus (GDM). <i>Scientific Reports</i> , 2018, 8, 12216.	3.3	162
22	Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis. <i>JAMA Internal Medicine</i> , 2017, 177, 633.	5.1	339
23	Effects of 6 months of resveratrol versus placebo on pentraxin 3 in patients with type 2 diabetes mellitus: a double-blind randomized controlled trial. <i>Acta Diabetologica</i> , 2017, 54, 499-507.	2.5	20
24	TM6SF2 rs58542926 variant affects postprandial lipoprotein metabolism and glucose homeostasis in NAFLD. <i>Journal of Lipid Research</i> , 2017, 58, 1221-1229.	4.2	40
25	MERTK rs4374383 variant predicts incident nonalcoholic fatty liver disease and diabetes: role of mononuclear cell activation and adipokine response to dietary fat. <i>Human Molecular Genetics</i> , 2017, 26, 1747-1758.	2.9	20
26	Dual therapy targeting the endocannabinoid system prevents experimental diabetic nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1655-1665.	0.7	42
27	Increased hepatic glucose production and insulin resistance are associated to increased plasma concentrations of glucogenic amino acids in subjects with NAFLD. <i>Digestive and Liver Disease</i> , 2017, 49, e1.	0.9	1
28	The acute impact of the intake of four types of bread on satiety and blood concentrations of glucose, insulin, free fatty acids, triglyceride and acylated ghrelin. A randomized controlled cross-over trial. <i>Food Research International</i> , 2017, 92, 40-47.	6.2	30
29	Letter by Musso et al Regarding Article, "Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus". <i>Circulation</i> , 2017, 136, 1563-1564.	1.6	0
30	Increased hepatic glucose production and insulin resistance in subjects with non-alcoholic fatty liver disease is associated to increased plasma concentrations of glucogenic amino acids. <i>Journal of Hepatology</i> , 2017, 66, S163.	3.7	0
31	New Pharmacologic Agents That Target Inflammation and Fibrosis in Nonalcoholic Steatohepatitis-Related Kidney Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 972-985.	4.4	26
32	Pioglitazone for advanced fibrosis in nonalcoholic steatohepatitis: New evidence, new challenges. <i>Hepatology</i> , 2017, 65, 1058-1061.	7.3	20
33	Different Serum Free Fatty Acid Profiles in NAFLD Subjects and Healthy Controls after Oral Fat Load. <i>International Journal of Molecular Sciences</i> , 2016, 17, 479.	4.1	70
34	Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2016, 63, 107-116.	7.3	67
35	Fatty Liver and Chronic Kidney Disease: Novel Mechanistic Insights and Therapeutic Opportunities. <i>Diabetes Care</i> , 2016, 39, 1830-1845.	8.6	129
36	Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial. <i>Pharmacological Research</i> , 2016, 111, 896-905.	7.1	120

#	ARTICLE	IF	CITATIONS
37	Predictive role of the Mediterranean diet on mortality in individuals at low cardiovascular risk: a 12-year follow-up population-based cohort study. <i>Journal of Translational Medicine</i> , 2016, 14, 91.	4.4	30
38	Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 249-274.	46.4	365
39	TM6SF2 may drive postprandial lipoprotein cholesterol toxicity away from the vessel walls to the liver in NAFLD. <i>Journal of Hepatology</i> , 2016, 64, 979-981.	3.7	15
40	PNPLA3 rs738409 and TM6SF2 rs58542926 gene variants affect renal disease and function in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2015, 62, 658-659.	7.3	47
41	Dietary flavonoid intake and cardiovascular risk: a population-based cohort study. <i>Journal of Translational Medicine</i> , 2015, 13, 218.	4.4	68
42	Isoleucine-to-methionine substitution at residue 148 variant of PNPLA3 gene and metabolic outcomes in gestational diabetes. <i>American Journal of Clinical Nutrition</i> , 2015, 101, 310-318.	4.7	6
43	Liver damage can be associated with deregulation of the de novo lipogenesis pathway in subjects with Non Alcoholic Fatty Liver Disease. <i>Digestive and Liver Disease</i> , 2015, 47, e5.	0.9	0
44	P0519 : Lipidomics reveals that low plasma unsaturated to saturated fat ratios are biomarkers of NAFLD and liver damage. <i>Journal of Hepatology</i> , 2015, 62, S509.	3.7	0
45	P1042 : Deregulation of de novo lipogenesis can be associated with liver damage in patients with non alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2015, 62, S738.	3.7	0
46	Trials of obeticholic acid for non-alcoholic steatohepatitis. <i>Lancet, The</i> , 2015, 386, 27.	13.7	6
47	Emerging Liver-Kidney Interactions in Nonalcoholic Fatty Liver Disease. <i>Trends in Molecular Medicine</i> , 2015, 21, 645-662.	6.7	96
48	Consuming More of Daily Caloric Intake at Dinner Predisposes to Obesity. A 6-Year Population-Based Prospective Cohort Study. <i>PLoS ONE</i> , 2014, 9, e108467.	2.5	117
49	Deficiency of cannabinoid receptor of type 2 worsens renal functional and structural abnormalities in streptozotocin-induced diabetic mice. <i>Kidney International</i> , 2014, 86, 979-990.	5.2	51
50	Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis. <i>PLoS Medicine</i> , 2014, 11, e1001680.	8.4	507
51	Simple lifestyle recommendations and the outcomes of gestational diabetes. A 2x2 factorial randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 1032-1035.	4.4	51
52	P846 SERUM FREE FATTY ACID COMPOSITION IS ASSOCIATED WITH DIFFERENT DEGREES OF FIBROSIS. <i>Journal of Hepatology</i> , 2014, 60, S353-S354.	3.7	0
53	P843 ALTERATION IN GLUCOSE METABOLISM AFTER AN ORAL GLUCOSE LOAD AND RELATIONSHIP WITH LIVER DAMAGE IN PATIENTS WITH NAFLD. <i>Journal of Hepatology</i> , 2014, 60, S352-S353.	3.7	0
54	P857 A NEW INDEX OF GLUTATHIONE TURNOVER (GSH_TI) AND ITS ASSOCIATION WITH SEVERITY OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD). <i>Journal of Hepatology</i> , 2014, 60, S357-S358.	3.7	0

#	ARTICLE	IF	CITATIONS
55	Alteration in glucose metabolism after an oral glucose load in patients with non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2014, 46, e54.	0.9	0
56	P849 QUANTITATIVE AND QUALITATIVE ANALYSIS OF PLASMA FREE FATTY ACIDS AND THEIR IMPACT ON LIVER DAMAGE IN NAFLD PATIENTS. <i>Journal of Hepatology</i> , 2014, 60, S354-S355.	3.7	0
57	Alteration in lipid metabolism after an oral fat load in non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2014, 46, e53-e54.	0.9	0
58	Effects of glucose and fat load on oxidative stress in patients with non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2014, 46, e54.	0.9	0
59	P845 IMPACT OF FAT VERSUS GLUCOSE LOAD ON OXIDATIVE STRESS IN NON-ALCOHOLIC FATTY LIVER DISEASE. <i>Journal of Hepatology</i> , 2014, 60, S353.	3.7	0
60	P840 ALTERATION IN LIPID METABOLISM AFTER AN ORAL FAT LOAD IN PATIENTS WITH NAFLD. <i>Journal of Hepatology</i> , 2014, 60, S352.	3.7	1
61	Gender specific medicine in liver diseases: A point of view. <i>World Journal of Gastroenterology</i> , 2014, 20, 2127.	3.3	47
62	Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver. <i>Trends in Molecular Medicine</i> , 2013, 19, 522-535.	6.7	68
63	Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Virologic Response in Patients With Genotype 1 Chronic Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 311-317.e1.	4.4	30
64	1351 CONTRIBUTION OF VISCERAL FAT AND HEPATIC FAT TO METABOLIC DERANGEMENTS AND LIVER DAMAGE IN NAFLD PATIENTS. <i>Journal of Hepatology</i> , 2013, 58, S543-S544.	3.7	0
65	1365 METABOLIC ALTERATIONS OF LIPID KINETICS IN NAFLD PATIENTS AND THEIR CONTRIBUTION TO LIVER DAMAGE. <i>Journal of Hepatology</i> , 2013, 58, S549.	3.7	0
66	Diabetes-specific variables associated with quality of life changes in young diabetic people: The type 1 diabetes Registry of Turin (Italy). <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2013, 23, 1031-1036.	2.6	12
67	Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. <i>Progress in Lipid Research</i> , 2013, 52, 175-191.	11.6	326
68	Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. <i>Obesity Reviews</i> , 2013, 14, 417-431.	6.5	194
69	Sterol Regulatory Element-Binding Factor 2 (<i>SREBF-2</i>) Predicts 7-Year NAFLD Incidence and Severity of Liver Disease and Lipoprotein and Glucose Dysmetabolism. <i>Diabetes</i> , 2013, 62, 1109-1120.	0.6	61
70	Impact of sterol regulatory element-binding factor-1c polymorphism on incidence of nonalcoholic fatty liver disease and on the severity of liver disease and of glucose and lipid dysmetabolism. <i>American Journal of Clinical Nutrition</i> , 2013, 98, 895-906.	4.7	43
71	Anti-Inflammatory and Antioxidant Effects of Resveratrol in Healthy Smokers A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial. <i>Current Medicinal Chemistry</i> , 2013, 20, 1323-1331.	2.4	159
72	Variations of serum levels of adiponectin and resistin in chronic viral hepatitis. <i>Journal of Endocrinological Investigation</i> , 2013, 36, 600-5.	3.3	13

#	ARTICLE	IF	CITATIONS
73	Obstructive Sleep Apnea-Hypopnea Syndrome and Nonalcoholic Fatty Liver Disease: Emerging Evidence and Mechanisms. <i>Seminars in Liver Disease</i> , 2012, 32, 049-064.	3.6	71
74	925 IL28B GENE VARIANTS AND METABOLIC PROFILE IN PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C. <i>Journal of Hepatology</i> , 2012, 56, S360.	3.7	0
75	Is left ventricular hypertrophy a low-level inflammatory state? A population-based cohort study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2012, 22, 668-676.	2.6	17
76	1310 PERIPHERAL INSULIN RESISTANCE RATHER THAN HEPATIC IS A PRIMARY DEFECT IN NON OBESE, NON DIABETIC, NON DYSLIPIDEMIC NAFLD PATIENTS: CORRELATION WITH LIVER DAMAGE. <i>Journal of Hepatology</i> , 2012, 56, S516.	3.7	0
77	Prognostic implications for insulin-sensitive and insulin-resistant normal-weight and obese individuals from a population-based cohort. <i>American Journal of Clinical Nutrition</i> , 2012, 96, 962-969.	4.7	50
78	Probiotics, Prebiotics, Energy Balance, and Obesity. <i>Gastroenterology Clinics of North America</i> , 2012, 41, 843-854.	2.2	34
79	A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials. <i>Annals of Medicine</i> , 2012, 44, 375-393.	3.8	247
80	Diagnostic accuracy of adipose insulin resistance index and visceral adiposity index for progressive liver histology and cardiovascular risk in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2012, 56, 788-789.	7.3	27
81	Nonalcoholic steatohepatitis versus steatosis: Adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism. <i>Hepatology</i> , 2012, 56, 933-942.	7.3	110
82	The rs553668 polymorphism of the <i>ADRA2A</i> gene predicts the worsening of fasting glucose values in a cohort of subjects without diabetes. A population-based study. <i>Diabetic Medicine</i> , 2012, 29, 549-552.	2.3	14
83	Gut Microbiota as a Modulator of Cardiometabolic Risk: Mechanisms and Therapeutic Implications. <i>Current Cardiovascular Risk Reports</i> , 2012, 6, 71-79.	2.0	2
84	Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. <i>Diabetologia</i> , 2012, 55, 885-904.	6.3	559
85	Redox Balance in the Pathogenesis of Nonalcoholic Fatty Liver Disease: Mechanisms and Therapeutic Opportunities. <i>Antioxidants and Redox Signaling</i> , 2011, 15, 1325-1365.	5.4	128
86	Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. <i>Annals of Medicine</i> , 2011, 43, 617-649.	3.8	1,098
87	Contributors to the obesity and hyperglycemia epidemics. A prospective study in a population-based cohort. <i>International Journal of Obesity</i> , 2011, 35, 1442-1449.	3.4	31
88	Interactions Between Gut Microbiota and Host Metabolism Predisposing to Obesity and Diabetes. <i>Annual Review of Medicine</i> , 2011, 62, 361-380.	12.2	515
89	Need for a three-focused approach to nonalcoholic fatty liver disease. <i>Hepatology</i> , 2011, 53, 1773-1773.	7.3	9
90	Loxin polymorphism is associated with increased resistin levels and with oxidative status. <i>Clinical Biochemistry</i> , 2011, 44, 1015-1017.	1.9	1

#	ARTICLE	IF	CITATIONS
91	Cholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease. <i>Current Opinion in Lipidology</i> , 2011, 22, 489-496.	2.7	41
92	Protective Role of Cannabinoid Receptor Type 2 in a Mouse Model of Diabetic Nephropathy. <i>Diabetes</i> , 2011, 60, 2386-2396.	0.6	123
93	Effect of lectin-like oxidized LDL receptor-1 polymorphism on liver disease, glucose homeostasis, and postprandial lipoprotein metabolism in nonalcoholic steatohepatitis. <i>American Journal of Clinical Nutrition</i> , 2011, 94, 1033-1042.	4.7	21
94	Nonalcoholic fatty liver disease from pathogenesis to management: an update. <i>Obesity Reviews</i> , 2010, 11, 430-445.	6.5	161
95	Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders. <i>Current Opinion in Lipidology</i> , 2010, 21, 76-83.	2.7	151
96	Emerging Molecular Targets for the Treatment of Nonalcoholic Fatty Liver Disease. <i>Annual Review of Medicine</i> , 2010, 61, 375-392.	12.2	77
97	Noninvasive assessment of liver disease severity with liver fat score and CK-18 in NAFLD: Prognostic value of liver fat equation goes beyond hepatic fat estimation. <i>Hepatology</i> , 2010, 51, 715-717.	7.3	32
98	A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010, 52, 79-104.	7.3	492
99	Lipoprotein metabolism mediates the association of MTP polymorphism with β -cell dysfunction in healthy subjects and in nondiabetic normolipidemic patients with nonalcoholic steatohepatitis. <i>Journal of Nutritional Biochemistry</i> , 2010, 21, 834-840.	4.2	36
100	Uncoupling protein 2 G(-866)A polymorphism: a new gene polymorphism associated with C-reactive protein in type 2 diabetic patients C-reactive protein in type 2 diabetic patients. <i>Cardiovascular Diabetology</i> , 2010, 9, 68.	6.8	11
101	Cannabinoid Receptor 1 Blockade Ameliorates Albuminuria in Experimental Diabetic Nephropathy. <i>Diabetes</i> , 2010, 59, 1046-1054.	0.6	130
102	Obesity, Diabetes, and Gut Microbiota. <i>Diabetes Care</i> , 2010, 33, 2277-2284.	8.6	557
103	Transcription Factor 7-Like 2 (TCF7L2) Polymorphism and Hyperglycemia in an Adult Italian Population-Based Cohort. <i>Diabetes Care</i> , 2010, 33, 1233-1235.	8.6	15
104	Prolonged saturated fat-induced, glucose-dependent insulinotropic polypeptide elevation is associated with adipokine imbalance and liver injury in nonalcoholic steatohepatitis: dysregulated enteroadipocyte axis as a novel feature of fatty liver. <i>American Journal of Clinical Nutrition</i> , 2009, 89, 558-567.	4.7	90
105	Effects of TCF7L2 polymorphisms on glucose values after a lifestyle intervention. <i>American Journal of Clinical Nutrition</i> , 2009, 90, 1502-1508.	4.7	21
106	Effect of the Monocyte Chemoattractant Protein-1/CC Chemokine Receptor 2 System on Nephron Expression in Streptozotocin-Treated Mice and Human Cultured Podocytes. <i>Diabetes</i> , 2009, 58, 2109-2118.	0.6	110
107	Iron supplementation and gestational diabetes in midpregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 2009, 201, 158.e1-158.e6.	1.3	55
108	Transcription factor 7-like 2 polymorphism modulates glucose and lipid homeostasis, adipokine profile, and hepatocyte apoptosis in NASH. <i>Hepatology</i> , 2009, 49, 426-435.	7.3	75

#	ARTICLE	IF	CITATIONS
109	Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. <i>Hepatology</i> , 2009, 50, 697-706.	7.3	140
110	What predicts the occurrence of the metabolic syndrome in a population-based cohort of adult healthy subjects?. <i>Diabetes/Metabolism Research and Reviews</i> , 2009, 25, 76-82.	4.0	16
111	Type 1 autoimmune hepatitis and adipokines: new markers for activity and disease progression?. <i>Journal of Gastroenterology</i> , 2009, 44, 476-482.	5.1	16
112	Phytosterol-enriched Yogurt Increases LDL Affinity and Reduces CD36 Expression in Polygenic Hypercholesterolemia. <i>Lipids</i> , 2009, 44, 153-60.	1.7	24
113	Plasma visfatin concentrations after a lifestyle intervention were directly associated with inflammatory markers. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2009, 19, 423-430.	2.6	19
114	Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). <i>Progress in Lipid Research</i> , 2009, 48, 1-26.	11.6	564
115	346 INCREASED LIVER EXPRESSION OF INFLAMMATORY MEDIATORS IS ASSOCIATED WITH HEPATIC INSULIN RESISTANCE IN LEAN, NON-DIABETIC PATIENTS WITH CHRONIC HEPATITIS C. <i>Journal of Hepatology</i> , 2009, 50, S133.	3.7	0
116	High-normal blood pressure is associated with a cluster of cardiovascular and metabolic risk factors: a population-based study. <i>Journal of Hypertension</i> , 2009, 27, 102-108.	0.5	26
117	Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: Possible pathogenetic role in NASH. <i>Hepatology</i> , 2008, 47, 1167-1177.	7.3	119
118	Associations between serum uric acid and adipokines, markers of inflammation, and endothelial dysfunction. <i>Journal of Endocrinological Investigation</i> , 2008, 31, 499-504.	3.3	32
119	Should Nonalcoholic Fatty Liver Disease Be Included in the Definition of Metabolic Syndrome? A Cross-Sectional Comparison With Adult Treatment Panel III Criteria in Nonobese Nondiabetic Subjects. <i>Diabetes Care</i> , 2008, 31, e43-e43.	8.6	4
120	Plasma Adiponectin Levels in Primary Biliary Cirrhosis: A Novel Perspective for Link Between Hypercholesterolemia and Protection Against Atherosclerosis. <i>American Journal of Gastroenterology</i> , 2008, 103, 1959-1965.	0.4	40
121	Incidence of Type 2 Diabetes Mellitus and Glucose Abnormalities in Patients With Chronic Hepatitis C Infection by Response to Treatment: Results of a Cohort Study. <i>American Journal of Gastroenterology</i> , 2008, 103, 2481-2487.	0.4	86
122	Should Nonalcoholic Fatty Liver Disease Be Included in the Definition of Metabolic Syndrome?. <i>Diabetes Care</i> , 2008, 31, 562-568.	8.6	185
123	Diet or exercise: what is more effective in preventing or reducing metabolic alterations?. <i>European Journal of Endocrinology</i> , 2008, 159, 685-691.	3.7	40
124	Association of liver disease with postprandial large intestinal triglyceride-rich lipoprotein accumulation and pro/antioxidant imbalance in normolipidemic non-alcoholic steatohepatitis. <i>Annals of Medicine</i> , 2008, 40, 383-394.	3.8	21
125	Associations of Dietary and Serum Copper with Inflammation, Oxidative Stress, and Metabolic Variables in Adults. <i>Journal of Nutrition</i> , 2008, 138, 305-310.	2.9	134
126	Efficacy of Antioxidant Treatment in Reducing Resistin Serum Levels: A Randomized Study. <i>PLOS Clinical Trials</i> , 2007, 2, e17.	3.5	27

#	ARTICLE	IF	CITATIONS
127	Oxidative Stress-mediated Mesangial Cell Proliferation Requires RAC-1/Reactive Oxygen Species Production and β 2 Integrin Expression. <i>Journal of Biological Chemistry</i> , 2007, 282, 26101-26110.	3.4	23
128	Nitrosative stress predicts the presence and severity of nonalcoholic fatty liver at different stages of the development of insulin resistance and metabolic syndrome: possible role of vitamin A intake. <i>American Journal of Clinical Nutrition</i> , 2007, 86, 661-671.	4.7	52
129	Magnesium intake, glucose and insulin serum levels in pre-school very-low-birth weight pre-term children. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2007, 17, 741-747.	2.6	5
130	Should we consider gestational diabetes a vascular risk factor?. <i>Atherosclerosis</i> , 2007, 194, e72-e79.	0.8	104
131	Polymorphism in microsomal triglyceride transfer protein: A link between liver disease and atherogenic postprandial lipid profile in NASH?. <i>Hepatology</i> , 2007, 45, 1097-1107.	7.3	112
132	Microsomal triglyceride transfer protein 493-T variant is associated with resistin levels and C-reactive protein. <i>Clinical Biochemistry</i> , 2007, 40, 1219-1224.	1.9	4
133	Insulin resistance in pre-school very-low-birth weight pre-term children. <i>Diabetes and Metabolism</i> , 2006, 32, 151-158.	2.9	14
134	Comparison of two enzyme immunometric assays to measure tumor necrosis factor-alpha in human serum. <i>Clinica Chimica Acta</i> , 2006, 364, 349-353.	1.1	7
135	Low-density lipoproteins are more electronegatively charged in type 1 than in type 2 diabetes mellitus. <i>Lipids</i> , 2006, 41, 529-533.	1.7	7
136	Association between postprandial LDL conjugated dienes and the severity of liver fibrosis in NASH. <i>Hepatology</i> , 2006, 43, 1169-1170.	7.3	10
137	Mild Gestational Hyperglycemia and the Metabolic Syndrome in Later Life. <i>Metabolic Syndrome and Related Disorders</i> , 2006, 4, 113-121.	1.3	13
138	p53 Mediates the Accelerated Onset of Senescence of Endothelial Progenitor Cells in Diabetes. <i>Journal of Biological Chemistry</i> , 2006, 281, 4339-4347.	3.4	137
139	The Postprandial Phase as a Link Between Systemic Lipid Peroxidation and Liver Injury in NASH This article has been retracted. <i>American Journal of Gastroenterology</i> , 2006, .	0.4	2
140	Plasma nitrotyrosine levels, antioxidant vitamins and hyperglycaemia. <i>Diabetic Medicine</i> , 2005, 22, 1185-1189.	2.3	21
141	Does C-reactive protein identify a subclinical metabolic disease in healthy subjects?.. <i>European Journal of Clinical Investigation</i> , 2005, 35, 265-270.	3.4	33
142	Relationships between human serum resistin, inflammatory markers and insulin resistance. <i>International Journal of Obesity</i> , 2005, 29, 1315-1320.	3.4	101
143	Adipokines in NASH: Postprandial lipid metabolism as a link between adiponectin and liver disease. <i>Hepatology</i> , 2005, 42, 1175-1183.	7.3	253
144	Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. <i>Diabetologia</i> , 2005, 48, 634-642.	6.3	642

#	ARTICLE	IF	CITATIONS
145	Apolipoprotein E Polymorphism and Stroke Subtypes in an Italian Cohort. <i>Cerebrovascular Diseases</i> , 2005, 20, 264-269.	1.7	16
146	Hypoadiponectinemia Predicts the Severity of Hepatic Fibrosis and Pancreatic Beta-Cell Dysfunction in Nondiabetic Nonobese Patients with Nonalcoholic Steatohepatitis. <i>American Journal of Gastroenterology</i> , 2005, 100, 2438-2446.	0.4	185
147	C-reactive protein and tumor necrosis factor- α in gestational hyperglycemia. <i>Journal of Endocrinological Investigation</i> , 2005, 28, 779-786.	3.3	47
148	Influence of cyclosporine on low-density lipoprotein uptake in human lymphocytes. <i>Metabolism: Clinical and Experimental</i> , 2005, 54, 1620-1625.	3.4	6
149	Associations between α -glutamyl transferase, metabolic abnormalities and inflammation in healthy subjects from a population-based cohort: A possible implication for oxidative stress. <i>World Journal of Gastroenterology</i> , 2005, 11, 7109.	3.3	70
150	RAGE and TGF β ² receptor-mediated signals converge on STAT5 and p21 waf to control cell-cycle progression of mesangial cells: a possible role in the development and progression of diabetic nephropathy. <i>FASEB Journal</i> , 2004, 18, 1249-1251.	0.5	52
151	Mild gestational hyperglycemia, the metabolic syndrome and adverse neonatal outcomes. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2004, 83, 335-340.	2.8	45
152	Platelet cGMP inversely correlates with age in healthy subjects. <i>Journal of Endocrinological Investigation</i> , 2004, 27, RC1-RC4.	3.3	8
153	In vivo oxidizability of LDL in type 2 diabetic patients in good and poor glycemic control. <i>Atherosclerosis</i> , 2004, 173, 103-107.	0.8	12
154	60 Metabolic significance of hepatic steatosis in non alcoholic fatty liver disease and HCV chronic hepatitis. <i>Journal of Hepatology</i> , 2004, 40, 21.	3.7	1
155	Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. <i>Hepatology</i> , 2003, 37, 909-916.	7.3	621
156	Dietary habits and their relations to insulin sensitivity in non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2003, 38, 197.	3.7	0
157	Obesity or diabetes: what is worse for the mother and for the baby?. <i>Diabetes and Metabolism</i> , 2003, 29, 175-178.	2.9	51
158	LDL Electronegativity Is Enhanced in Type 1 Diabetes. <i>Diabetes Care</i> , 2003, 26, 2214-2215.	8.6	2
159	Lipoprotein-apolipoprotein changes in renal transplant recipients. <i>Lipids</i> , 2002, 37, 967-974.	1.7	6
160	Plasma homocysteine, methylenetetrahydrofolate reductase gene polymorphism and carotid intima-media thickness in Italian type 2 diabetic patients. <i>European Journal of Clinical Investigation</i> , 2002, 32, 24-28.	3.4	32
161	Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association. <i>Hepatology</i> , 2002, 35, 367-372.	7.3	644
162	Diabetic LDL inhibits cell-cycle progression via STAT5B and p21waf. <i>Journal of Clinical Investigation</i> , 2002, 109, 111-119.	8.2	21

#	ARTICLE	IF	CITATIONS
163	STAT5 Activation Induced by Diabetic LDL Depends on LDL Glycation and Occurs Via src Kinase Activity. <i>Diabetes</i> , 2002, 51, 3311-3317.	0.6	24
164	Diabetic LDL inhibits cell-cycle progression via STAT5B and p21waf. <i>Journal of Clinical Investigation</i> , 2002, 109, 111-119.	8.2	8
165	Postprandial triglyceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients. <i>Lipids</i> , 2001, 36, 1117-1124.	1.7	83
166	Resistant Hypertriglyceridemia in a Patient With High Plasma Levels of Apolipoprotein CII. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 2329-2339.	2.4	6
167	Study of the glycosylation of apolipoprotein H. <i>Chemistry and Physics of Lipids</i> , 1999, 103, 161-174.	3.2	7
168	Apolipoprotein H is not affected by in vitro glycosylation. <i>The Protein Journal</i> , 1999, 18, 173-177.	1.1	1
169	The binding of apolipoprotein H (β^2 -Glycoprotein I) to lipoproteins. <i>Prostaglandins and Other Lipid Mediators</i> , 1999, 57, 351-359.	1.9	12
170	Human lipoprotein lipase HindIII polymorphism in young patients with myocardial infarction. <i>Metabolism: Clinical and Experimental</i> , 1999, 48, 1157-1161.	3.4	19
171	Glycosylation of Apolipoprotein H. , 1998, 14, 202-206.		0
172	Characterization and representative structures of N-oligosaccharides bound to apolipoprotein H. <i>Journal of Lipid Mediators and Cell Signalling</i> , 1997, 17, 191-205.	0.9	5
173	Apolipoprotein H levels in diabetic subjects: Correlation with cholesterol levels. <i>Metabolism: Clinical and Experimental</i> , 1997, 46, 522-525.	3.4	21
174	Qualitative analysis of the carbohydrate composition of apolipoprotein H. <i>The Protein Journal</i> , 1997, 16, 205-212.	1.1	11
175	Influence of APOH protein polymorphism on apoH levels in normal and diabetic subjects. <i>Clinical Genetics</i> , 1997, 52, 167-172.	2.0	5
176	Postprandial triglyceride-rich lipoprotein changes in elderly and young subjects. <i>Aging Clinical and Experimental Research</i> , 1996, 8, 421-428.	2.9	22
177	Apolipoprotein H: a two-step isolation method. <i>Journal of Lipid Research</i> , 1996, 37, 902-904.	4.2	10
178	Apolipoprotein H: a two-step isolation method. <i>Journal of Lipid Research</i> , 1996, 37, 902-4.	4.2	8
179	Apolipoprotein E allele frequencies in an Italian population: Relation to age and lipid profile. <i>Aging Clinical and Experimental Research</i> , 1995, 7, 185-189.	2.9	11
180	Influence of apolipoprotein H polymorphism on levels of triglycerides. <i>Atherosclerosis</i> , 1994, 110, 45-51.	0.8	71

#	ARTICLE	IF	CITATIONS
181	Lipoprotein-apolipoprotein changes in renal transplant recipients: A 2-year follow-up. <i>Metabolism: Clinical and Experimental</i> , 1991, 40, 922-925.	3.4	17